AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9524457 — intervention group
Group type: EXPERIMENTAL
Intervention: Completely sealed surfaces (optimal sealant coverage)
Number of subjects: 402
Study 9524457 — intervention group
Group type: COMPARATOR
Intervention: Inadequately sealed surfaces
Number of subjects: 402
Study 9524457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants with optimal coverage at final examination
Number of subjects: 402
Study 8262084 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and nifedipine fixed combination
Number of subjects: 114
Study 8262084 — intervention group
Group type: COMPARATOR
Intervention: Atenolol alone
Number of subjects: 114
Study 3085136 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg fluphenazine decanoate
Number of subjects: 45
Study 3085136 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg fluphenazine decanoate
Number of subjects: 45
Study 3085136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dosage groups (5 mg and 25 mg)
Number of subjects: 45
Study 31741360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 606
Study 31741360 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 606
Study 29056392 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute continuous chest compressions
Number of subjects: 36
Study 29056392 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute continuous chest compressions
Number of subjects: 36
Study 29056392 — intervention group
Group type: COMPARATOR
Intervention: 1-minute vs 2-minute groups
Number of subjects: 36
Study 26862696 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin, 60 mg/kg, intravenously as a single dose 3 days before and after transplant conditioning regimen cycle
Number of subjects: 46
Study 26862696 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo treatment)
Number of subjects: 46
Study 26862696 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 46
Study 25229957 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Family Therapy (SFT)
Number of subjects: 40
Study 22476908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 T CMR
Number of subjects: 34
Study 22476908 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 T CMR
Number of subjects: 34
Study 22476908 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 34
Study 21417122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone pretreatment
Number of subjects: 48
Study 21417122 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fissure sealant (Fissurit F) with ozone pretreatment
Number of subjects: 48
Study 21417122 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Clearfil Protect Bond) with ozone pretreatment
Number of subjects: 48
Study 17592913 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy
Number of subjects: 49
Study 17592913 — intervention group
Group type: COMPARATOR
Intervention: Applied Relaxation Training
Number of subjects: 49
Study 16518702 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype carrying patients
Number of subjects: 0
Study 16518702 — intervention group
Group type: COMPARATOR
Intervention: AG genotype carrying patients
Number of subjects: 0
Study 11954869 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A from original bulk toxin source
Number of subjects: 133
Study 11954869 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A from current bulk toxin source
Number of subjects: 133
Study 10413279 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic RBCs (n = 17)
Number of subjects: 47
Study 10413279 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs (n = 14)
Number of subjects: 47
Study 8689462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) - 5 injections at weekly intervals
Number of subjects: 63
Study 8689462 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular triamcinolone hexacetonide (TH) - 20 mg followed by 4 placebo (saline) injections
Number of subjects: 63
Study 2088110 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline
Number of subjects: 210
Study 2088110 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 210
Study 698165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg cyanocobalamin injection, three times weekly for 6 weeks
Number of subjects: 31
Study 698165 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection, three times weekly for 6 weeks
Number of subjects: 31
Study 30664093 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP), 16 sessions, 3 days per week for 6 weeks
Number of subjects: 30
Study 30664093 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 30
Study 29282009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg orally three times daily from recruitment to 32 weeks gestation
Number of subjects: 0
Study 29282009 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets orally three times daily from recruitment to 32 weeks gestation
Number of subjects: 0
Study 25476463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative prism adaptation test (PAT) performed in 18 patients (Group 1)
Number of subjects: 38
Study 25476463 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative prism adaptation test (Group 2)
Number of subjects: 38
Study 23278907 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch method
Number of subjects: 171
Study 23278907 — intervention group
Group type: COMPARATOR
Intervention: Classical sterile method
Number of subjects: 171
Study 21191143 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g essential amino acids with 10 g l-arginine (ARG)
Number of subjects: 8
Study 21191143 — intervention group
Group type: COMPARATOR
Intervention: isonitrogenous control (CON)
Number of subjects: 8
Study 20053252 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 2397
Study 20053252 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 2397
Study 17876177 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized information intervention
Number of subjects: 324
Study 17876177 — intervention group
Group type: COMPARATOR
Intervention: Generic information intervention
Number of subjects: 324
Study 15235055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Atrial Natriuretic Peptide (ANP)
Number of subjects: 58
Study 15235055 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional therapy (Control)
Number of subjects: 58
Study 14564675 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucoselect‐Phytosome (LP)
Number of subjects: 24
Study 10670160 — intervention group
Group type: COMPARATOR
Intervention: SF6‐gas tamponade
Number of subjects: 54
Study 10670160 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone‐oil tamponade
Number of subjects: 54
Study 7474675 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict blood pressure control (DBP 65 to 80 mm Hg)
Number of subjects: 87
Study 7474675 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood pressure control (DBP 85 to 95 mm Hg)
Number of subjects: 87
Study 7474675 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analysis of combined outcomes
Number of subjects: 87
Study 1964599 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral acyclovir therapy for the suppression of recurrent genital herpes simplex virus infection
Number of subjects: 48
Study 1964599 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral acyclovir therapy
Number of subjects: 48
Study 377878 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin with regular insulin
Number of subjects: 10
Study 377878 — intervention group
Group type: EXPERIMENTAL
Intervention: PZI insulin with regular insulin
Number of subjects: 10
Study 31860606 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose stellate ganglion block (SGB) with 5 ml of 0.5% ropivacaine
Number of subjects: 90
Study 31860606 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose stellate ganglion block (SGB)
Number of subjects: 90
Study 31860606 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 29670279 — intervention group
Group type: COMPARATOR
Intervention: F-652 (2.0 µg/kg, SC)
Number of subjects: 6
Study 29670279 — intervention group
Group type: EXPERIMENTAL
Intervention: F-652 (IV infusion at 2.0, 10, 30, and 45 µg/kg)
Number of subjects: 6
Study 29670279 — intervention group
Group type: EXPERIMENTAL
Intervention: F-652 (IV infusion)
Number of subjects: 6
Study 29670279 — intervention group
Group type: EXPERIMENTAL
Intervention: F-652 (45 µg/kg, IV)
Number of subjects: 6
Study 28936675 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconnection to mechanical ventilation for 1 hour after successful spontaneous breathing trial (rest group)
Number of subjects: 470
Study 28936675 — intervention group
Group type: COMPARATOR
Intervention: Direct extubation (control group)
Number of subjects: 470
Study 25440265 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+filter
Number of subjects: 716
Study 25440265 — intervention group
Group type: EXPERIMENTAL
Intervention: CS
Number of subjects: 716
Study 25440265 — intervention group
Group type: EXPERIMENTAL
Intervention: filter
Number of subjects: 716
Study 25440265 — intervention group
Group type: COMPARATOR
Intervention: neither CS nor filter
Number of subjects: 716
Study 23684013 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous blood (ABI) alone
Number of subjects: 48
Study 23684013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramaxillary fixation (IMF) alone for 4 weeks
Number of subjects: 48
Study 23684013 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous blood (ABI) and intramaxillary fixation (IMF) for 4 weeks
Number of subjects: 48
Study 21063429 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF: 14.1 g/l protein, 662 kcal/l)
Number of subjects: 336
Study 21063429 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (EF: 12.8 g/l protein, 662 kcal/l)
Number of subjects: 336
Study 21063429 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 336
Study 19302900 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 100 mg/mo
Number of subjects: 370
Study 19302900 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 150 mg/mo
Number of subjects: 370
Study 19302900 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 200 mg/mo
Number of subjects: 370
Study 19302900 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg/d (active control)
Number of subjects: 370
Study 19302900 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 370
Study 19302900 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 150 mg/mo and 200 mg/mo
Number of subjects: 370
Study 19302900 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg/d
Number of subjects: 370
Study 17316103 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed training (written text-graphic directions for use with patient-assistance phone number)
Number of subjects: 102
Study 17316103 — intervention group
Group type: COMPARATOR
Intervention: Intensive training (same DFU, personal training by study personnel, inspiratory flow rate coaching)
Number of subjects: 102
Study 17316103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training methods (self-directed and intensive)
Number of subjects: 102
Study 17316103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training
Number of subjects: 102
Study 15355142 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional words in reading, lexical decision, and color naming tasks
Number of subjects: 0
Study 15355142 — intervention group
Group type: COMPARATOR
Intervention: Neutral words in a single block
Number of subjects: 0
Study 11150007 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 42
Study 11150007 — intervention group
Group type: COMPARATOR
Intervention: Partial sleep deprivation (PSD)
Number of subjects: 42
Study 10049522 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferons (IFN) beta and gamma in combination with hormonotherapy (Megace or Tamoxifen)
Number of subjects: 0
Study 10049522 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of sIL‐2R and of IFN‐gamma
Number of subjects: 0
Study 8281698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus anticoagulation (aspirin 162.5 mg daily plus heparin followed by aspirin 162.5 mg daily plus warfarin)
Number of subjects: 214
Study 8281698 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (162.5 mg daily)
Number of subjects: 214
Study 8281698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (aspirin plus anticoagulation)
Number of subjects: 214
Study 30502489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine strain (mumps vaccine)
Number of subjects: 570
Study 30502489 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type virus
Number of subjects: 570
Study 30502489 — intervention group
Group type: COMPARATOR
Intervention: Vaccine strain vs Wild-type virus
Number of subjects: 570
Study 27402475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (250,000 IU, one-time oral dose)
Number of subjects: 28
Study 27402475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 25967093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified work-related rehabilitation aftercare program (including functional capacity training, psychosocial groups, social counseling, relaxation training, and exercise therapy)
Number of subjects: 307
Study 25967093 — intervention group
Group type: COMPARATOR
Intervention: Standard intensified rehabilitation aftercare (consisting of only exercise therapy)
Number of subjects: 307
Study 25967093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified work-related rehabilitation aftercare program
Number of subjects: 307
Study 25967093 — intervention group
Group type: COMPARATOR
Intervention: Standard intensified rehabilitation aftercare
Number of subjects: 307
Study 25549015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (as a drug)
Number of subjects: 0
Study 25549015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22910440 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (C/P) plus motesanib
Number of subjects: 1400
Study 22910440 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (C/P) plus bevacizumab
Number of subjects: 1400
Study 22910440 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel (C/P)
Number of subjects: 1400
Study 19184059 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 3103
Study 19184059 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 3103
Study 16950885 — intervention group
Group type: EXPERIMENTAL
Intervention: Élite racing drivers
Number of subjects: 18
Study 16950885 — intervention group
Group type: COMPARATOR
Intervention: Physically active controls
Number of subjects: 18
Study 15202299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic and glucocorticoid therapy
Number of subjects: 43
Study 15202299 — intervention group
Group type: COMPARATOR
Intervention: Before therapy
Number of subjects: 43
Study 11330583 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 50
Study 11330583 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery hemorrhoidectomy
Number of subjects: 50
Study 9264147 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg/day)
Number of subjects: 10
Study 9264147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8302150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg epidural morphine in 10 mL normal saline with epinephrine 0.1 mg (1:100,000, 10 micrograms/mL)
Number of subjects: 60
Study 8302150 — intervention group
Group type: COMPARATOR
Intervention: 2 mg epidural morphine in 10 mL normal saline without epinephrine
Number of subjects: 60
Study 3731824 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg sustained-release oxprenolol once daily
Number of subjects: 30
Study 3731824 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide/50 mg triamterene once daily
Number of subjects: 30
Study 3731824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 160 mg sustained-release oxprenolol and 25 mg hydrochlorothiazide/50 mg triamterene once daily
Number of subjects: 30
Study 3731824 — intervention group
Group type: COMPARATOR
Intervention: 160 mg sustained-release oxprenolol alone
Number of subjects: 30
Study 3731824 — intervention group
Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide/50 mg triamterene alone
Number of subjects: 30
Study 3731824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 30
Study 3731824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide treatment
Number of subjects: 30
Study 31504090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating sweets (n = 60)
Number of subjects: 150
Study 31504090 — intervention group
Group type: COMPARATOR
Intervention: Calorie-equivalent bland food (n = 60)
Number of subjects: 150
Study 31504090 — intervention group
Group type: COMPARATOR
Intervention: Watching a video (n = 30)
Number of subjects: 150
Study 28815997 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily sustained-release (SR) paracetamol (2 × 1000 mg twice daily)
Number of subjects: 28
Study 28815997 — intervention group
Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 28
Study 27514255 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to abnormal acceleration of sea state
Number of subjects: 60
Study 25008861 — intervention group
Group type: EXPERIMENTAL
Intervention: B haplotypes (activating KIR genes)
Number of subjects: 517
Study 22811926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules (1 capsule/day) for 6 months after a wash-out period
Number of subjects: 20
Study 22811926 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 20
Study 22811926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules (1 capsule/day)
Number of subjects: 20
Study 20173092 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-1 (50 microM)
Number of subjects: 0
Study 20173092 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-2 (50 microM)
Number of subjects: 0
Study 20173092 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-3 (200 microM)
Number of subjects: 0
Study 20173092 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-1 (100 microM)
Number of subjects: 0
Study 20173092 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-2 (100 microM)
Number of subjects: 0
Study 20173092 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-3 (100 microM)
Number of subjects: 0
Study 18489612 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg for 1 week
Number of subjects: 15
Study 18489612 — intervention group
Group type: COMPARATOR
Intervention: Atropine (nonselective muscarinic antagonist)
Number of subjects: 15
Study 16003020 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study 16003020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study 11849656 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 253
Study 11849656 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACE D homozygotes)
Number of subjects: 253
Study 11849656 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study 10528882 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nitrate levels during acute gastroenteritis
Number of subjects: 43
Study 10528882 — intervention group
Group type: COMPARATOR
Intervention: Plasma nitrate levels during acute pneumonia
Number of subjects: 43
Study 10528882 — intervention group
Group type: COMPARATOR
Intervention: Plasma nitrate levels during febrile urinary tract infection
Number of subjects: 43
Study 10528882 — intervention group
Group type: COMPARATOR
Intervention: Plasma nitrate levels in 20 patients with severe pneumonia or UTI
Number of subjects: 43
Study 7746935 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation with an inspiratory mask
Number of subjects: 85
Study 2386447 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 mg)
Number of subjects: 16
Study 2386447 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine (1.0 mg)
Number of subjects: 16
Study 2386447 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 7389389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg 3-times daily
Number of subjects: 101
Study 7389389 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 250 mg 3-times daily
Number of subjects: 101
Study 31775843 — intervention group
Group type: EXPERIMENTAL
Intervention: SHGBZK treatment
Number of subjects: 100
Study 31775843 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 30249190 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast MRI
Number of subjects: 416
Study 30249190 — intervention group
Group type: COMPARATOR
Intervention: Noncontrast US
Number of subjects: 416
Study 27835963 — intervention group
Group type: EXPERIMENTAL
Intervention: Moulded flip-flop footwear (Foot Bio-Tec©) with a moulded foot-bed
Number of subjects: 108
Study 27835963 — intervention group
Group type: COMPARATOR
Intervention: Footwear education and instructions to wear their normal footwear
Number of subjects: 108
Study 27835963 — intervention group
Group type: EXPERIMENTAL
Intervention: Moulded flip-flop footwear (Foot Bio-Tec©)
Number of subjects: 108
Study 24599676 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy plus physical therapy (n=37)
Number of subjects: 81
Study 24599676 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone (n=44)
Number of subjects: 81
Study 22383668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study 22383668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0